Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In re: Janssen Biotech, Inc.
Case Number:
17-1257
Court:
Nature of Suit:
Companies
Sectors & Industries:
-
January 23, 2018
Fed. Circ. Backs PTAB's Invalidation Of J&J Remicade Patent
The Federal Circuit on Tuesday upheld a Patent Trial and Appeal Board decision invalidating a Johnson & Johnson patent on the blockbuster autoimmune disease drug Remicade for double patenting, in a win for Pfizer Inc., which launched a biosimilar version in 2016.
-
October 03, 2017
J&J Unit Fights To Save Remicade Patent At Fed. Circ.
A Johnson & Johnson subsidiary urged the Federal Circuit on Tuesday to reverse a decision invalidating a patent on its blockbuster autoimmune disease drug Remicade for double-patenting, saying the finding conflicts with a 1994 law changing the length of patent terms.